Page last updated: 2024-12-06

haba

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(4-hydroxyphenylazo)benzoic acid : An azo compound that is azobenzene in which one phenyl group is substituted at position 4 by a hydroxy group, while the other phenyl group is substituted at position 2 by a carboxy group. It is used as a matrix in matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID74215
CHEMBL ID1442125
CHEBI ID64341
SCHEMBL ID453284
SCHEMBL ID2868736
SCHEMBL ID12100493
MeSH IDM0041585

Synonyms (82)

Synonym
2-(4-hydroxyphenylazo)benzoic acid
MLS001066404
smr000471883
hbaba
benzoic acid, o-((p-hydroxyphenyl)azo)-
2-((4'-hydroxyphenyl)azo)benzoic acid
benzoic acid, 2-((4-hydroxyphenyl)azo)-
2-(p-hydroxyphenylazo)benzoic acid
2-(4'-hydroxybenzene)azobenzoic acid
nsc 77376
benzoic acid, 2-(2-(4-hydroxyphenyl)diazenyl)-
einecs 216-655-2
nsc77376
2-[(4-hydroxyphenyl)azo]benzoic acid
nsc-77376
o-(p-hydroxyphenylazo)benzoic acid
1634-82-8
haba
benzoic acid, 2-[(4-hydroxyphenyl)azo]-
benzoic acid, o-[(p-hydroxyphenyl)azo]-
2-(4-hydroxybenzeneazo)benzoic acid
o-[(p-hydroxyphenyl)azo]-benzoic acid
2-((4'-hydroxyphenyl)-azo)benzoic acid
HAB ,
1SRE
NCIOPEN2_004156
MLS001174930 ,
2-(4-hydroxyphenylazo)benzoic acid, >=98% (tlc)
DB07880
2-[2-(4-oxocyclohexa-2,5-dien-1-ylidene)hydrazinyl]benzoic acid
4'-hydroxyazobenzene-2-carboxylic acid
4-hydroxyazobenzene-2'-carboxylic acid
H0586
AKOS000121378
NCGC00245994-01
HMS2232A03
2-[2-(4-hydroxyphenyl)diazen-1-yl]benzoic acid
2-(4'-hydroxyphenylazo)benzoic acid
2-[(4-hydroxyphenyl)diazenyl]benzoic acid
CHEBI:64341
FT-0608649
SCHEMBL453284
SCHEMBL2868736
H1622
DTXSID9061837
SCHEMBL12100493
CHEMBL1442125
DWQOTEPNRWVUDA-CCEZHUSRSA-N
2-[(4-hydroxyphenyl)diazenyl]benzoic acid #
o-[(p-hydroxyphenyl)azo]benzoic acid
4'-hydroxy-phenylazo-2-benzoic acid
haba (dye)
bdbm67445
2-[2-(4-oxidanylidenecyclohexa-2,5-dien-1-ylidene)hydrazinyl]benzoic acid
2-[2-(4-oxo-1-cyclohexa-2,5-dienylidene)hydrazinyl]benzoic acid
cid_5357439
2-[n''-(4-ketocyclohexa-2,5-dien-1-ylidene)hydrazino]benzoic acid
AKOS028109285
mfcd00002428
2-(4-hydroxyphenylazo)benzoic acid, matrix substance for maldi-ms, >=99.5% (hplc), ultra pure
2-(4-hydroxyphenylazo)benzoic acid, matrix substance for maldi-ms, >=99.5%
2-((4-hydroxyphenyl)diazenyl)benzoic acid
J-010048
2-[(e)-(4-hydroxyphenyl)diazenyl]benzoic acid
Q27097088
4'-hydroxyazobenzene-2-carboxylic acid [matrix for maldi-tof/ms]
(z)-2-((4-hydroxyphenyl)diazenyl)benzoic acid
EN300-16636
PS-10347
Q27455492
2-(4-hydroxyphenylazo)-benzoic acid
D90910
benzoic acid, 2-[2-(4-hydroxyphenyl)diazenyl]-
853296-55-6
(e)-2-((4-hydroxyphenyl)diazenyl)benzoic acid
PD004926
PD036638
2-(4 inverted exclamation marka-hydroxyphenylazo)benzoic acid
CS-0309179
haba, hbaba
Z56347243
SY057029

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of biotin to protein avidin was evaluated by a 4'-hydroxyazobenzene-2-carboxylic acid/avidin (HABA/avidin) binding assay and TEM."( Biotinylated thermoresponsive core cross-linked nanoparticles via RAFT polymerization and "click" chemistry.
Liu, L; Liu, Y; Luo, Y; Lv, W; Wang, X, 2011
)
0.58
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (4 Product(s))

Product Categories

Product CategoryProducts
Other1
oats1
Drycker, Kolsyrade Drycker, en:Artificially sweetened beverages, Energidrycker, en:Unsweetened beverages1
Grassi, Grassi animali, Lardo1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency44.66840.631035.7641100.0000AID504339
Nrf2Homo sapiens (human)Potency31.62280.09208.222223.1093AID624171
thioredoxin reductaseRattus norvegicus (Norway rat)Potency89.12510.100020.879379.4328AID588453
GLS proteinHomo sapiens (human)Potency28.18380.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency20.25500.000811.382244.6684AID686978; AID686979
IDH1Homo sapiens (human)Potency20.59620.005210.865235.4813AID686970
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency79.43280.354828.065989.1251AID504847
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency29.09290.00419.984825.9290AID504444
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency29.93490.168316.404067.0158AID720504
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency25.11890.425612.059128.1838AID504891
gemininHomo sapiens (human)Potency10.87720.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RevHuman immunodeficiency virus 1IC50 (µMol)22.02008.31208.92059.5290AID434976
Female germline-specific tumor suppressor gld-1Caenorhabditis elegansIC50 (µMol)8.40101.47104.96148.4010AID2802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
insulin-degrading enzyme isoform 1Homo sapiens (human)EC50 (µMol)24.58352.02605.17858.9430AID588439; AID588681
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (56)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (33.93)18.7374
1990's9 (16.07)18.2507
2000's18 (32.14)29.6817
2010's9 (16.07)24.3611
2020's1 (1.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 72.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index72.61 (24.57)
Research Supply Index4.08 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index194.77 (26.88)
Search Engine Supply Index3.15 (0.95)

This Compound (72.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.72%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other57 (98.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]